IDH-Mutant Gliomas: Therapeutic Strategies and Clinical Outcomes

IDH-mutant gliomas represent a molecularly defined subgroup of diffuse gliomas characterised by gain-of-function alterations in the isocitrate dehydrogenase (IDH) enzymes. The resultant accumulation of the oncometabolite 2-hydroxyglutarate (2-HG) drives widespread epigenetic remodelling and perturbs cellular differentiation programmes. Clinically, the presence of an IDH mutation confers a more favourable prognosis than in IDH-wildtype counterparts, yet recurrence remains almost universal despite maximal safe resection, radiotherapy and alkylating chemotherapy. Over the past decade, therapeutic strategies have evolved from non-selective cytotoxic approaches towards targeted inhibition of mutant IDH, exploitation of DNA-repair vulnerabilities and immunotherapeutic modulation of the tumour microenvironment. Early-phase clinical trials of small-molecule inhibitors have demonstrated on-target metabolic suppression, blood–brain barrier penetration and preliminary antitumour activity, setting the stage for phase III studies. Parallel efforts to leverage IDH-driven “BRCAness” through PARP inhibition and to combine mutant IDH blockade with other modalities are beginning to inform personalised treatment paradigms. Collectively, these advances promise to refine outcome prediction, guide patient stratification and extend survival in a globally significant patient population.

Research from Nature Portfolio

Recent studies have evaluated two first-generation mutant IDH inhibitors in a perioperative setting for non-enhancing, recurrent low-grade gliomas. Both agents produced a greater than 90 % reduction in intratumoral 2-HG levels, accompanied by reversal of DNA hypermethylation and attenuation of gene expression programmes linked to stemness and proliferation. The compound with superior brain penetrance demonstrated more consistent metabolic suppression and was advanced into a pivotal phase III trial in patients with newly diagnosed, non-irradiated IDH-mutant low-grade gliomas. Safety profiles across both agents were favourable, with reversible liver enzyme elevations as the principal dose-limiting toxicity. Exploratory immunophenotyping revealed an influx of activated myeloid and lymphoid populations within treated tumours, suggesting potential synergy with immunotherapeutic strategies.

IDH-Mutant Gliomas: Therapeutic Strategies and Clinical Outcomes publication trend

The graph below shows the total number of articles in idh-mutant gliomas: therapeutic strategies and clinical outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

IDH mutation: A gain-of-function alteration in isocitrate dehydrogenase 1 or 2 that produces the oncometabolite 2-hydroxyglutarate.

2-Hydroxyglutarate (2-HG): A metabolite accumulating in IDH-mutant cells that induces widespread epigenetic and metabolic dysregulation.

Progression-free survival (PFS): The length of time during and after treatment in which a patient’s disease does not worsen.

Oligodendroglioma: A subtype of glioma defined by 1p/19q co-deletion and IDH mutation, generally associated with better prognosis.

Astrocytoma: A glioma subtype arising from astrocytic glial cells, graded by histological and molecular features.

PARP inhibitor: A drug targeting poly(ADP-ribose) polymerase enzymes to exploit defective DNA-repair pathways in cancer cells.

References

1. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nature Medicine (2023).
2. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell (2024).
3. Multicenter Phase 2 Trial of the PARP Inhibitor Olaparib in Recurrent IDH1 and IDH2-Mutant Glioma. Cancer Research Communications (2023).